{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:15:02Z","timestamp":1772115302898,"version":"3.50.1"},"reference-count":40,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Foundation for Science and Technology (Portugal)","award":["UIDB\/00313\/2020"],"award-info":[{"award-number":["UIDB\/00313\/2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Clinical practice entails a translation of research that assists in the use of scientific data and therapeutic evidence for the benefit of the patient. This review critically summarizes the potential impact of cannabinoids in conjunction with other drugs when associated with treatments for epilepsy, autism spectrum disorder, cancer, multiple sclerosis, and chronic pain. In these associations, potential drug interactions may occur and alter the predicted clinical results. Therefore, the potential for drug interactions must always be assessed to avoid therapeutic failures and\/or increased side effects. Some effects may be additive, synergistic, or antagonistic, but changes in absorption, distribution, metabolism, particularly through cytochrome P450 (CYP) isoenzymes (e.g., CYP2C9 and CYP3A4), and excretion may also occur. For example, the combination of cannabis-derived compounds and the antifungal drug ketoconazole, a CYP3A4 inhibitor, increases the plasma concentration of \u0394-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). In contrast, rifampicin, a CYP3A4 inducer, stands out for reducing plasma THC levels by approximately 20\u201340% and 50% to 60% for CBD. Other CYP3A4 inhibitors and inducers are likely to have a similar effect on plasma concentrations if co-administered. Pharmacokinetic interactions with anticonvulsant medications have also been reported, as have pharmacodynamic interactions between cannabinoids and medications with sympathomimetic effects (e.g., tachycardia, hypertension), central nervous system depressants (e.g., drowsiness, ataxia), and anticholinergics (e.g., tachycardia and somnolence). Although further studies are still pending, there is currently clinical evidence supporting drug interactions with cannabinoids, requiring doctors to evaluate the risk of drug combinations with cannabinoids and vice versa. The tables provided here were designed to facilitate the identification of biorelevant interactions that may compromise therapeutic efficacy and toxicity.<\/jats:p>","DOI":"10.3390\/ph17050613","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:25:47Z","timestamp":1715318747000},"page":"613","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Drug\u2013Cannabinoid Interactions in Selected Therapeutics for Symptoms Associated with Epilepsy, Autism Spectrum Disorder, Cancer, Multiple Sclerosis, and Pain"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1012-6240","authenticated-orcid":false,"given":"Maria G.","family":"Campos","sequence":"first","affiliation":[{"name":"Observatory of Drug-Herb Interactions, Faculty of Pharmacy, University of Coimbra, Health Science Campus, Azinhaga Santa Comba, 3000-548 Coimbra, Portugal"},{"name":"Coimbra Chemistry Centre (CQC, FCT Unit 313) (FCTUC), University of Coimbra, Rua Larga, 3004-531 Coimbra, Portugal"}]},{"given":"Maria","family":"China","sequence":"additional","affiliation":[{"name":"Observatory of Drug-Herb Interactions, Faculty of Pharmacy, University of Coimbra, Health Science Campus, Azinhaga Santa Comba, 3000-548 Coimbra, Portugal"}]},{"given":"Mariana","family":"Cl\u00e1udio","sequence":"additional","affiliation":[{"name":"Observatory of Drug-Herb Interactions, Faculty of Pharmacy, University of Coimbra, Health Science Campus, Azinhaga Santa Comba, 3000-548 Coimbra, Portugal"}]},{"given":"Miguel","family":"Capinha","sequence":"additional","affiliation":[{"name":"Observatory of Drug-Herb Interactions, Faculty of Pharmacy, University of Coimbra, Health Science Campus, Azinhaga Santa Comba, 3000-548 Coimbra, Portugal"}]},{"given":"Rita","family":"Torres","sequence":"additional","affiliation":[{"name":"Observatory of Drug-Herb Interactions, Faculty of Pharmacy, University of Coimbra, Health Science Campus, Azinhaga Santa Comba, 3000-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1422-8106","authenticated-orcid":false,"given":"Sim\u00e3o","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Observatory of Drug-Herb Interactions, Faculty of Pharmacy, University of Coimbra, Health Science Campus, Azinhaga Santa Comba, 3000-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-6639","authenticated-orcid":false,"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[{"name":"Observatory of Drug-Herb Interactions, Faculty of Pharmacy, University of Coimbra, Health Science Campus, Azinhaga Santa Comba, 3000-548 Coimbra, Portugal"},{"name":"Laboratory of Pharmacology and Pharmaceutical Care, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"CIBIT\u2014Coimbra Institute for Biomedical Imaging and Translational Research, ICNAS, University of Coimbra, 3000-548 Coimbra, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"ref_1","first-page":"598","article-title":"Cannabis Essentials: Tools for Clinical Practice","volume":"104","author":"Sazegar","year":"2021","journal-title":"Am. Fam. Physician"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000528528","article-title":"CANNabinoid Drug Interaction Review (CANN-DIRTM)","volume":"6","author":"Kocis","year":"2023","journal-title":"Med. Cannabis Cannabinoids"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.amjmed.2019.05.017","article-title":"Cannabis and Cannabinoids: Kinetics and Interactions","volume":"132","author":"Foster","year":"2019","journal-title":"Am. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lopera, V., Rodr\u00edguez, A., and Amariles, P. (2022). Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051154"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1007\/s11606-020-06504-8","article-title":"Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: A Comprehensive Review","volume":"36","author":"Balachandran","year":"2021","journal-title":"J. Gen. Intern. Med."},{"key":"ref_7","first-page":"207","article-title":"Interactions between drugs and herbal teas","volume":"Volume 1","author":"Ramos","year":"2018","journal-title":"Food-Drug Interactions: Pharmacokinetics, Prevention and Potential Side Effects"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/03602532.2013.849268","article-title":"Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review","volume":"46","author":"Stout","year":"2014","journal-title":"Drug Metab. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.37201\/req\/013.2023","article-title":"Recommendations on the use of azole antifungals in hematology-oncology patients","volume":"36","author":"Azanza","year":"2023","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/14737175.2021.1834383","article-title":"Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome","volume":"21","author":"Lattanzi","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Khayat, W., and Lehmann, C. (2022). The Endocannabinoid System: A Potential Therapeutic Target for Coagulopathies. Metabolites, 12.","DOI":"10.3390\/metabo12060541"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pediatrneurol.2019.11.017","article-title":"Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex","volume":"105","author":"Agricola","year":"2020","journal-title":"Pediatr. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40263-019-00683-7","article-title":"Clinically Significant Drug\u2013Drug Interactions with Agents for Attention-Deficit\/Hyperactivity Disorder","volume":"33","author":"Schoretsanitis","year":"2019","journal-title":"CNS Drugs"},{"key":"ref_15","unstructured":"McNeil, S.E., Gibbons, J.R., and Cogburn, M. (2022). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Alsherbiny, M.A., Bhuyan, D.J., Low, M.N., Chang, D., and Li, C.G. (2021). Synergistic interactions of cannabidiol with chemotherapeutic drugs in mcf7 cells: Mode of interaction and proteomics analysis of mechanisms. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221810103"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Dobovi\u0161ek, L., Krstanovi\u0107, F., Bor\u0161tnar, S., and Debeljak, N. (2020). Cannabinoids and hormone receptor-positive breast cancer treatment. Cancers, 12.","DOI":"10.3390\/cancers12030525"},{"key":"ref_18","first-page":"S62","article-title":"Drug-Drug Interaction (DDI) Studies with Coadministration of Cannabidiol (CBD) and Clobazam (CLB), Valproate (VPA), Stiripentol (STP) or Midazolam (MDZ) in Healthy Volunteers (HVTs) and Adults with Epilepsy","volume":"86","author":"Gidal","year":"2019","journal-title":"Ann. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pediatrneurol.2020.01.005","article-title":"Dravet Syndrome: A Review of Current Management","volume":"107","author":"Wheless","year":"2020","journal-title":"Pediatr. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.seizure.2020.09.010","article-title":"Interaction of cannabidiol with other antiseizure medications: A narrative review","volume":"86","author":"Gilmartin","year":"2021","journal-title":"Seizure"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40263-020-00726-4","article-title":"A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug\u2013Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy","volume":"34","author":"Gunning","year":"2020","journal-title":"CNS Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.yebeh.2019.07.008","article-title":"Drug\u2013drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program","volume":"98","author":"Gaston","year":"2019","journal-title":"Epilepsy Behav."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0039-1695786","article-title":"Cannabidiol Interacts Significantly with Everolimus\u2014Report of a Patient with Tuberous Sclerosis Complex","volume":"50","author":"Stiller","year":"2019","journal-title":"Neuropediatrics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"107733","DOI":"10.1016\/j.neuropharm.2019.107733","article-title":"Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies","volume":"158","author":"Wyska","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Brown, J., and Winterstein, A. (2019). Potential Adverse Drug Events and Drug\u2013Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. J. Clin. Med., 8.","DOI":"10.3390\/jcm8070989"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","article-title":"A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1124\/dmd.119.090092","article-title":"Abemaciclib does not have a clinically meaningful effect on pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 substrates in patients with cancer","volume":"48","author":"Hall","year":"2020","journal-title":"Drug Metab. Dispos."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1002\/j.1552-4604.1981.tb02576.x","article-title":"Nabilone: An Effective Antiemetic in Patients Receiving Cancer Chemotherapy","volume":"21","author":"Einhorn","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/bjc.1983.247","article-title":"Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy","volume":"48","author":"Ahmedzai","year":"1983","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bph.12439","article-title":"Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT 1A receptors without diminishing nervous system function or chemotherapy efficacy Correspondence","volume":"171","author":"Ward","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41523-023-00570-x","article-title":"CBD-oil as a potential solution in case of severe tamoxifen-related side effects","volume":"9","author":"Buijs","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/bcp.15701","article-title":"Cannabidiol\u2013drug interaction in cancer patients: A retrospective study in a real-life setting","volume":"89","author":"Guedon","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_35","unstructured":"Baker, S.D., Wirth, M., Statkevich, P., Reidenberg, P., Alton, K., Sartorius, S.E., Dugan, M., Cutler, D., Batra, V., and Grochow, L.B. (2023, October 27). Absorption, Metabolism, and Excretion of 14 C-Temozolomide following Oral Administration to Patients with Advanced Cancer 1. Available online: http:\/\/aacrjournals.org\/clincancerres\/article-pdf\/5\/2\/309\/2071717\/df029900309.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/rheumatology\/kez304","article-title":"Important drug interactions exist between cannabidiol oil and commonly prescribed drugs in rheumatology practice","volume":"59","author":"Sien","year":"2020","journal-title":"Rheumatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/FPC.0000000000000392","article-title":"PharmGKB summary: Sertraline pathway, pharmacokinetics","volume":"30","author":"Huddart","year":"2020","journal-title":"Pharmacogen. Genom."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13643-020-01415-5","article-title":"Evidence Synthesis International (ESI): Position Statement","volume":"9","author":"Gough","year":"2020","journal-title":"Syst. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"950","DOI":"10.11124\/JBIES-21-00483","article-title":"What are scoping reviews? Providing a formal definition of scoping reviews as a type of evidence synthesis","volume":"20","author":"Munn","year":"2022","journal-title":"JBI Evid. Synth."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kacemi, R., and Campos, M.G. (2023). Translational Research on Bee Pollen as a Source of Nutrients: A Scoping Review from Bench to Real World. Nutrients, 15.","DOI":"10.3390\/nu15102413"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/5\/613\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:43:26Z","timestamp":1760107406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/5\/613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ph17050613"],"URL":"https:\/\/doi.org\/10.3390\/ph17050613","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]}}}